Purpose: To investigate dosimetric differences among several clinical treatment planning systems ͑TPS͒ and Monte Carlo ͑MC͒ codes for brachytherapy of intraocular tumors using 125 I or 103 Pd plaques, and to evaluate the impact on the prescription dose of the adoption of MC codes and certain versions of a TPS ͑Plaque Simulator with optional modules͒. Methods: Three clinical brachytherapy TPS capable of intraocular brachytherapy treatment planning and two MC codes were compared. The TPS investigated were Pinnacle v8.0dp1, BrachyVision v8.1, and Plaque Simulator v5.3.9, all of which use the AAPM TG-43 formalism in water. The Plaque Simulator software can also handle some correction factors from MC simulations. The MC codes used are MCNP5 v1.40 and BrachyDose/EGSnrc. Using these TPS and MC codes, three types of calculations were performed: homogeneous medium with point sources ͑for the TPS only, using the 1D TG-43 dose calculation formalism͒; homogeneous medium with line sources ͑TPS with 2D TG-43 dose calculation formalism and MC codes͒; and plaque heterogeneity-corrected line sources ͑Plaque Simulator with modified 2D TG-43 dose calculation formalism and MC codes͒. Comparisons were made of doses calculated at points-of-interest on the plaque central-axis and at off-axis points of clinical interest within a standardized model of the right eye. Results: For the homogeneous water medium case, agreement was within ϳ2% for the point-and line-source models when comparing between TPS and between TPS and MC codes, respectively. For the heterogeneous medium case, dose differences ͑as calculated using the MC codes and Plaque Simulator͒ differ by up to 37% on the central-axis in comparison to the homogeneous water calculations. A prescription dose of 85 Gy at 5 mm depth based on calculations in a homogeneous medium delivers 76 Gy and 67 Gy for specific Pd, respectively. There was good agreement ͑ϳ3%͒ among MC codes and Plaque Simulator results when appropriate parameters calculated using MC codes were input into Plaque Simulator. Plaque Simulator and MC users are perhaps at risk of overdosing patients up to 20% if heterogeneity corrections are used and the prescribed dose is not modified appropriately. Conclusions: Agreement within 2% was observed among conventional brachytherapy TPS and MC codes for intraocular brachytherapy dose calculations in a homogeneous water environment. In general, the magnitude of dose errors incurred by ignoring the effect of the plaque backing and Silastic insert ͑i.e., by using the TG-43 approach͒ increased with distance from the plaque's centralaxis. Considering the presence of material heterogeneities in a typical eye plaque, the best method in this study for dose calculations is a verified MC simulation.
I or 103 Pd plaques, and to evaluate the impact on the prescription dose of the adoption of MC codes and certain versions of a TPS ͑Plaque Simulator with optional modules͒. Methods: Three clinical brachytherapy TPS capable of intraocular brachytherapy treatment planning and two MC codes were compared. The TPS investigated were Pinnacle v8.0dp1, BrachyVision v8.1, and Plaque Simulator v5.3.9, all of which use the AAPM TG-43 formalism in water. The Plaque Simulator software can also handle some correction factors from MC simulations. The MC codes used are MCNP5 v1.40 and BrachyDose/EGSnrc. Using these TPS and MC codes, three types of calculations were performed: homogeneous medium with point sources ͑for the TPS only, using the 1D TG-43 dose calculation formalism͒; homogeneous medium with line sources ͑TPS with 2D TG-43 dose calculation formalism and MC codes͒; and plaque heterogeneity-corrected line sources ͑Plaque Simulator with modified 2D TG-43 dose calculation formalism and MC codes͒. Comparisons were made of doses calculated at points-of-interest on the plaque central-axis and at off-axis points of clinical interest within a standardized model of the right eye. Results: For the homogeneous water medium case, agreement was within ϳ2% for the point-and line-source models when comparing between TPS and between TPS and MC codes, respectively. For the heterogeneous medium case, dose differences ͑as calculated using the MC codes and Plaque Simulator͒ differ by up to 37% on the central-axis in comparison to the homogeneous water calculations. A prescription dose of 85 Gy at 5 mm depth based on calculations in a homogeneous medium delivers 76 Gy and 67 Gy for specific 125 I and 103 Pd sources, respectively, when accounting for COMS-plaque heterogeneities. For off-axis points-of-interest, dose differences approached factors of 7 and 12 at some positions for 125 I and 103 Pd, respectively. There was good agreement ͑ϳ3%͒ among MC codes and Plaque Simulator results when appropriate parameters calculated using MC codes were input into Plaque Simulator. Plaque Simulator and MC users are perhaps at risk of overdosing patients up to 20% if heterogeneity corrections are used and the prescribed dose is not modified appropriately. Conclusions: Agreement within 2% was observed among conventional brachytherapy TPS and MC codes for intraocular brachytherapy dose calculations in a homogeneous water environment. In general, the magnitude of dose errors incurred by ignoring the effect of the plaque backing and
I. INTRODUCTION
Recent advances in dose calculation methods have drawn attention to limitations of the current AAPM TG-43 dosimetry formalism under certain circumstances.
1-3 Dosimetry of eye plaques ͑used for the treatment of intraocular tumors͒ is one of these circumstances because of the following reasons: significant material inhomogeneities relative to water are involved, the eye is a small structure ͑ϳ2.5 cm diam.͒, and the points of interest are at distances as close as 1 mm from the radioactive sources. Furthermore, investigations have demonstrated that dose distributions in the eye are critical in determining location and incidence of side-effects. 4, 5 Prior to 1986, there was no consensus approach for radiotherapy of choroidal melanoma resulting in the use of widely different techniques at various institutions. At that time, the Collaborative Ocular Melanoma Study ͑COMS͒, a multiinstitutional cooperative clinical trial sponsored by the National Eye Institute of the National Institutes of Health ͑Be-thesda, MD͒, was started. The COMS trial compared enucleation against a minimum of 100 Gy 125 I plaque radiation therapy for medium-sized choroidal melanomas ͑i.e., between 2.5 mm and 10 mm in height and Ͻ16 mm basal diameter͒. 6, 7 With no difference in survival found between treatment arms after 12 years of follow up, the COMS clearly established 125 I plaque brachytherapy as an effective eye-and vision-sparing treatment for choroidal melanoma. 8 The most recent publications on trial outcomes can be found in COMS Reports Nos. 24 and 28 published in 2004 and 2006, respectively. 8, 9 In 1996, the dose prescription of 100 Gy ͑based on pre-TG-43 dosimetry͒ was revised to 85 Gy following the introduction of the TG-43 formalism. 10, 11 This dose was prescribed to the tumor apex when the tumor apex was Ն5 mm, and to 5 mm when the tumor apex was Ͻ5 mm. In 2003, the American Brachytherapy Society recommended prescribing to the tumor apex for all mediumsized choroidal melanomas, even those Ͻ5 mm in height. 12 In the 1990s, Chiu-Tsao et al. 13, 14 and de la Zerda et al. 15 reported thermoluminescent dosimeter ͑TLD͒ measurements and Monte Carlo ͑MC͒ radiation transport simulations of the dose distributions in an eye phantom for a single 125 I and 103 Pd source in a COMS-plaque. These groups observed central-axis dose reductions of ϳ10% and ϳ16% for 125 I and 103 Pd, respectively, and off-axis dose reductions up to 30%. They attributed these reductions to the presence of the plaque's Silastic insert ͑silicone polymer seed carrier͒ and the gold-alloy ͑Modulay͒ backing ͑where the term backing includes the plaque collimating lip͒. Being 40% silicon by weight, Silastic has an effective-atomic number Z ef f = 10.7 ͑substantially greater than that of water at 7.42 or air at 7.63͒ and consequently attenuates low-energy photons more than water via the photoelectric effect.
The COMS medium-tumor trial dosimetry was reanalyzed by Krintz et al. in 2003 to investigate the impact of source anisotropy, the line-source approximation for the geometry function, radiation collimation by the plaque gold-alloy lip, and 10% dose reduction by the Silastic insert using an earlier version of Astrahan's Plaque Simulator ͑PS͒ software ͑dis-tributed by IBt Bebig, Berlin, Germany͒. 16, 17 The reanalysis determined that corrected dose calculations resulted in a significant and consistent reduction of between 7% and 21% compared to COMS-calculated values for points of interest within the eye; supporting the earlier results of Chiu-Tsao et al. 13 Based on the TG-43 algorithm with a semianalytical method to incorporate additional scatter and attenuation factors, PS accounts for the effects of the gold-alloy backing and attenuation from the Silastic. More recent versions of PS software 18 included the correction factors which depend on the path length of primary radiation in Silastic and gold-alloy and the distance between the calculation point and radioactive seed. For fully loaded 12 mm and 20 mm plaques, Astrahan reconfirmed in 2005 that the calculated doses to critical ocular structures ranged from 16% to 50% less than would have been reported using the standard COMS dose calculation protocol.
Older MC radiation transport codes such as those using MORSE had limited geometry packages, physics models, and computing power. 13 However, current MC codes take advantage of more powerful computing systems that allow the simulation of complex brachytherapy environments such as eye plaques. 19, 20 The objective of this study is to present a dosimetric comparison of modern MC simulations and conventional brachytherapy treatment planning systems ͑TPSs͒ using a 16 mm diameter COMS plaque ͑Fig. 1͒. The current study focuses on the impact of modern MC methods on the administered dose for the treatment of intraocular tumors.
II. MATERIALS AND METHODS
Three TG-43-based TPS capable of intraocular radiotherapy planning ͑Pinnacle v8.0dp1, 21 BrachyVision v8. ͑a͒ Line-Homo: Superposition of dose contributions from single seeds based on the line-source approximation ͑TG-43 2D formalism͒ in an unbounded, homogeneous water phantom. ͑b͒ MC-Homo: Dose distributions from seeds in an unbounded, homogeneous water phantom using MCNP5 and BrachyDose ͑with no interseed effects͒ were calculated for comparison to the TG-43-based calculations, i.e., ͑2a͒.
͑3͒ Line source in heterogeneous media. This approach accounted for radiological perturbations by the gold-alloy backing and the Silastic insert.
͑a͒ PS-Hetero: Superposition of single seed 2D dose contributions based on the line-source approximation in an unbounded water phantom with a semianalytical correction for plaque attenuation and scatter ͑using input from MC simulations͒ was performed using for comparison to the full MC simulations, i.e., ͑3b͒. ͑b͒ MC-Hetero: Full MC simulations of detailed models of all seeds ͑including interseed effects͒ and the plaque ͑gold-alloy backing and Silastic insert͒ in an unbounded water phantom were performed using MCNP5 and BrachyDose with the level of detail described in Refs. 19 and 20.
II.A. TG-43-based brachytherapy treatment planning
In calculation method ͑1a͒ above, the 1D formalism utilized a 1D anisotropy function of unity at all radii r as in an ͑r͒ =1 ͓Eq. ͑1͔͒, while calculation method ͑2a͒ above used the 2D formalism ͓Eq. ͑2͔͒, where all symbols for dosimetry parameters have the standard meanings from the 2004 AAPM TG-43U1 report,
Log-linear interpolation was used to obtain radial dose function g P ͑r͒ and g L ͑r͒ data for TPS input data with the 1D and 2D formalisms, respectively, for 59 data points between 1.0 mmՅ r Յ 30.0 mm in 0.5 mm steps. The same r range with resolution of 10°was generally used for the 2D anisotropy function F͑r , ͒ with bilinear-linear interpolation over r and . study are in good agreement with the data of Taylor et al. 28, 29 Due to limited precision of data entry by some TPS, especially for the dose-rate constant ⌳, the model 6711 125 I source was described with an active length L of 2.8 mm, half-life of 59.4 days, ⌳ = 0.96 cGy h −1 U −1 , and air-kerma strength S K = 4.572 U. These parameters were chosen to obtain a dose of approximately 85 Gy for an irradiation time of 100 h to a central-axis depth d of 5 mm where the distance d is the distance along the plaque central-axis from the inner sclera ͑in contrast with r which is the distance from the coordinate system origin of each source͒. Similarly, the model 200 103 Pd source was described with L = 4.23 mm, half-life of 16.99 days, ⌳ = 0.69 cGy h −1 U −1 , and S K = 3.879 U to obtain approximately 85 Gy to d = 5 mm for an irradiation time of 168 h. These irradiation times were taken as representative for readily available source strengths of 125 I and 103 Pd. Source strengths up to 6.8 U for 103 Pd are available with short lead-times, resulting in irradiation times closer to the 100 hours used for 125 I in this study. Details concerning the three TG-43 based TPS ͑i.e., Pinnacle, BrachyVision, and PS͒ are outlined below. The degree of agreement among TPS depends partially on the fact that all systems used the same input data which in turn were consistent with the MC calculations performed in water. If different data were input, the results ͑given below͒ may not be in such good agreement.
II.A.1. Pinnacle
Brachytherapy dose calculations using Pinnacle ͑Philips Medical Systems, Cleveland, OH͒ were performed with version 8.0dp1; although, the brachytherapy dose calculation module has not changed between version 6.0g ͑2001͒ and version 9 ͑2009͒. The g P ͑r͒, g L ͑r͒, and F͑r , ͒ values were tabulated for 0.5 mmՅ r Յ 30.0 mm in 0.5 mm steps ͑60 entries͒, and 5°angular sampling was used for F͑r , ͒ ͑1140 total entries͒. When using a dose grid of 0.5 mm or 1.5 mm, or with F͑r , ͒ having 5°or 10°sampling, dose values at all positions remained constant within 0.5%. Along-and-away lookup tables for all source models were calculated using 0.1 mm steps between 0.0 mm and 30.0 mm, utilizing 90,601 data points per source model. While the TG-43 calculation methodology was utilized to generate the lookup table, the table was subsequently employed in treatment planning calculations using the superposition principle. A dose calculation grid of 0.5 mm was set within the application for the display of isodose lines.
II.A.2. BrachyVision
Brachytherapy dose calculations for both 103 Pd and 125 I sources were performed using two different versions ͑6.1 and 8.1͒ of BrachyVision ͑Varian Medical Systems, Palo Alto, CA͒. In comparison to version 6.1, version 8.1 has higher precision in dosimetry parameter data entry. Further, the newer version corrected truncation errors of source coordinates and point-dose calculations. Consequently, only v.8.1 results are included herein. A 1.0 mm dose grid was specified. Values of g P ͑r͒ and g L ͑r͒ were entered with spatial resolutions of 0.5 mm for 0.5 mmՅ r Յ 10 mm and at 5 mm for 15 mmՅ r Յ 50 mm, totaling 28 entries. Values of F͑r , ͒ had 5°resolution for 0°Յ Յ 90°, and 1.0 mm radial resolution for 1 mmՅ r Յ 50 mm, utilizing 950 entries. It was found that using smaller radial and angular increments altered results by Ͻ0.2%.
II.A.3. Plaque Simulator
Brachytherapy dose calculations were performed using version 5.3.9 of PS. For the model 6711 125 I seed, g P ͑r͒ and g L ͑r͒ values were entered at 0.5 mm intervals for 0.5 mm Յ r Յ 3 mm, at 1 mm intervals for 4 mmՅ r Յ 10 mm, and at 5 mm intervals for 15 mmՅ r Յ 40 mm. Values of F͑r , ͒ values were entered at 5°intervals and at seven radial distances, r = 2.5, 5, 10, 20, 30, 40, and 50 mm. For the model 200 103 Pd seed, g P ͑r͒ and g L ͑r͒ values were entered using the following radial spacing: r = 1, 1.5, 2, 2.5, 3, 4, 5, 7.5, and 10 mm, and 5 mm intervals for 15 mmՅ r Յ 40 mm. The values of F͑r , ͒ were entered at nonuniform intervals in order to provide more angular detail near the source long-axis at = 0°, 1°, 2°, 3°, 5°, 7°, 10°, 12°, 15°, 20°, 25°, 30°, 40°, 50°, 60°, 70°, 75°, 80°, 85°, and 90°and r = 2.5, 5, 10, 20, 30, 40, and 50 mm. The dose grid was 0.25 mm.
Besides the TG-43-based dose calculation, plaque heterogeneity correction functions were incorporated in the PS dose calculation using optional modules. Dose collimation by the lip on the gold-alloy backing was enabled. The analytical dose correction function T͑r͒ was used in dose calculations for individual seeds to account for combined effects of the gold-alloy backing and Silastic carrier insert. Values of T͑r͒ were obtained from a fit to the dose ratio with and without the gold-alloy backing and Silastic insert for a single seed in the center slot of a 20 mm COMS plaque as obtained from MC calculations by Thomson and Rogers using the BrachyDose code. 30 Based on the results obtained by Thomson et al., 20 these dose ratios vary by less than 1% for 12 mm and 20 mm plaques over the range of interest, thus allowing a single table for each seed model appropriate for use with all plaque sizes. In combination with T͑r͒, an additional path length correction was used to account for oblique Silastic thicknesses greater than 1 mm.
II.B. Monte Carlo eye plaque simulations
For the MC simulations, absorbed dose was approximated as collision kerma due to the low photon energies and short secondary charged particle ͑electron͒ ranges. Section II A lists the radionuclide half-lives, seed S K values, and irradiation times used subsequent to MC simulations of the dose per history to determine the dose for the specified treatment times. To ensure consistent normalization with TPS dose calculations, MC-derived doses were scaled by the ratio ⌳ / ⌳ MC , where ⌳ was the value of the dose-rate constant used for TPS dose calculations and ⌳ MC was the value of the dose-rate constant derived with the appropriate MC code 19, 20 which differed slightly ͑e.g., by Ϫ3.8% and ϩ0.6% for 125 I and II.B.1. MCNP5 The MCNP5 ͑v1.40͒ simulations were performed according to the methods of Melhus and Rivard for a fully loaded 16 mm COMS eye plaque containing either 125 I model 6711 or 103 Pd model 200 brachytherapy sources. 19 The simulations employed the same plaque and seed geometry, but varied the tally mesh ͑a track-length estimate of the particle flux averaged over a mesh cell͒ to include a lateral extent of Ϯ12.4 mm and longitudinal extent ͑parallel to the centralaxis͒ from Ϫ5 mm to 24.2 mm with ͑0.2 mm͒ 3 cubic voxels. A total of 10 9 particles were simulated to achieve centralaxis statistical uncertainties ͑k =1͒ of Ͻ0.5% at the inner sclera, 0.9% at d = 5 mm on the central-axis, and 2% at the opposite retina.
II.B.2. BrachyDose
The EGSnrc user-code BrachyDose ͑BD͒ was used to perform MC simulations which fully modeled brachytherapy seeds and COMS-plaques. 20 Seed models in homogeneous water medium were previously benchmarked. 28, 29 Plaques were simulated at the center of a cubic water phantom of edge length 300 mm. Dose was scored in ͑0.5 mm͒ 3 cubic voxels using a track-length estimator. Simulations with 10 10 histories were performed, resulting in statistical uncertainties ͑k =1͒ of Ͻ0.05% at the inner sclera, Ͻ0.1% at d = 5 mm on the central-axis ͑tumor apex͒, and 0.5% at the opposite retina and other points of interest.
II.C. Plaque and eye models
The dose-distribution calculations were limited to a 16 mm COMS-plaque at different positions on the eye. Based on clinical experience, the 16 mm COMS plaque is one of the most frequently used plaque sizes among the various COMS sizes currently available from 10 mm to 22 mm diameters, in 2 mm increments. 12 With the assumptions used in the COMS, the right eye was modeled as a 24.6 mm diameter water sphere. The inner sclera and outer sclera were set to d = 0 mm and d = −1 mm, respectively, along the central-axis. The plaque and eye schematic shown in Fig. 1 depict positions where doses were calculated. The plaque was loaded with 13 radioactive seeds as shown in Fig. 2 . Centers of the sources were placed at a radius of 13.7 mm in a Silastic insert with a total thickness of 2.2 mm and an approximate 1 mm cover for each seed. The Silastic density was taken as 1.12 g / cm 3 and its composition was taken as 6.3% H, 24.9% C, 28.9% O, 39.9% Si, and 0.005% Pt by weight. 13 The coordinates of 13 seeds, including seed centers and end points, are listed in Table I For the first four positions ͓͑1͒-͑4͔͒, "centered on equator" means the plaque's central-axis is on the equatorial plane of a standardized right eye. For the second four positions ͓͑5͒-͑8͔͒, "posterior to equator" means that the plaque's center is between the equatorial plane and the posterior pole where the macula and fovea are located. The corresponding retinal diagrams, also called fundus diagrams, 31 for these eight tumor and plaque positions are shown in Fig. 3 Table I . For each plaque, there are six suture lugs shown on the right side of the plaque.
III. RESULTS

III.A. Central-axis
Table II presents absolute dose along the plaque's centralaxis calculated by each method using the initial conditions described in Sec. II. Taken as the average of the standard deviation of doses from the mean at points along the centralaxis, agreement among the Point-Homo methods for 125 I and 103 Pd is 0.1% and 0.5%, respectively, with 0.6% and 1.1% agreement among Line-Homo methods, respectively. At any point on the central-axis, the average of doses calculated with the three Point-Homo and five Line-Homo approaches differed negligibly ͑ϳ0.1%͒ for 125 I and ϳ1% for 103 Pd. At each depth the average dose calculated by the three TPS was generally within 2% of that calculated by the MC codes for both seed-types examined, which is within the expected total dosimetric uncertainties for these techniques. The average dose ratio of PS-Hetero to MC-Hetero along the central-axis ͑−1 mmϽ d Ͻ 22.6 mm͒ is 0.991Ϯ 0.010 for 125 I and 1.010Ϯ 0.019 for 103 Pd. The last column of Table II 103 Pd. These dose reductions, due to the plaque's heterogeneity effects, are in agreement with those observed by Melhus and Rivard 19 and by Thomson et al. 20 The magnitudes of dose reductions on the central-axis, in particular, the dose reductions of 9 Gy and 18 Gy at the prescription point ͑d =5 mm͒ for 125 I and 103 Pd, respectively, are significant. However, these dose differences have been present all along and indicate the most accurate estimate of the current administered dose given a current written directive prescribing 85 Gy to d = 5 mm using the AAPM TG-43 dose calculation formalism.
III.B. Off-axis
For off-axis locations and the different plaque positions investigated, Table III presents the average results from the different TPS and MC codes for each calculation type ͑i.e., Point-Homo, Line-Homo, and MC-Hetero͒. As expected, doses at off-axis points of interest in a homogeneous medium are lower for line-source approximations as compared to point-source approximations. The largest deviations are found at the lacrimal gland center, where the line-source approximation results in 10% and 20% less dose than the pointsource approximation for 125 I and 103 Pd sources, respectively. The inclusion of plaque heterogeneities from the goldalloy backing and Silastic insert ͑i.e., MC-Hetero͒ causes dose reductions of approximately 20%-30% for most points of interest, and up to 92% ͑a factor of 12͒ dose reductions at off-axis positions such as the lacrimal gland center ͑positions #1 and #3, Table III͒. Doses to the four points of interest for organs at risk are considerably lower for 103 Pd than for 125 I for all eight plaque configurations.
At positions #5-#8 ͑Table III͒, the maximum point of interest doses using the MC-Hetero technique are for the fovea and optic disk and are approximately 59 Gy and 48 Gy for 125 I and 45 Gy and 35 Gy for 103 Pd, respectively. When visual acuity is an important end point, dose to these structures should be minimized. In this case, the accuracy of dose calculation can have a major influence on the magnitude of corrections due to the limitations of TG-43 based methods TABLE I. Coordinates ͑millimeters͒ of seeds in the 16 mm COMS standard eye plaque. The seed physical length was set to 4.5 mm. Physical positioning of the seed # assignment is shown in Fig. 2 . The COMS reference coordinate system origin at ͑x p =0, y p =0, z p =0͒ is defined at the inner sclera along the plaque's central-axis. For MC calculations, the slightly longer 6711 seeds were centered with the same orientation. Pd, these corrections are approximately 25% and 42%, respectively. Figure 4 illustrates the calculated dose-discrepancies between homogenous and heterogeneous approaches with BD data for a 16 mm COMS plaque located at position #1. The isodose contours ͓Figs. 4͑a͒ and 4͑b͔͒ are more conformal to the tumor volume for BD-Hetero than for BD-Homo calculations for both radionuclides. Figures 4͑a͒ and 4͑b͒ also illustrate the more rapid dose fall-off with distance from the plaque for 103 Pd than for 125 I, in accord with the results of Thomson et al. , 20 Thomson and Rogers, 30 and Melhus and Rivard.
19 Doses to critical points of interest and to regions surrounding the eye are lower with 103 Pd ͑model 200͒ than for 125 I ͑model 6711͒, with the exception of the inner sclera; 20 Thomson and Rogers reported lower doses to critical normal structures and surrounding tissues for all 103 Pd seed models than for 125 I seed models except at the sclera adjacent the plaque where doses vary with seed model and are not always higher for 103 Pd than for 125 I. 30 Figures 4͑c͒ and 4͑d͒ show the percentage difference for BD-Homo and BD-Hetero dose distributions; dose differences are significant in all regions of the eye and are particularly large in the plaque penumbral-region.
IV. DISCUSSION
Although only the 16 mm COMS plaque is examined in this study, others have reported on dose variations as a function of plaque diameter. 19, 20 Central-axis MC heterogeneity corrections suggest that the ratio of heterogeneous to homogeneous dose calculations does not vary appreciably as a function of plaque diameter. 19, 20 Melhus and Rivard 19 observed that the ratio of heterogeneous to homogeneous 
͑MCNP͒ version 1.40, and BrachyDose ͑BD͒. Values are calculated using Point-Homo and Line-Homo for the 1D and 2D TG-43 dosimetry formalisms, respectively, using homogeneous water phantoms, and PS-Hetero and MC-Hetero using heterogeneous phantoms. The ratio of average MC-Hetero/Point-Homo ͑with MC-Hetero equal to the average MCNP and BD results͒ is given in the last column. central-axis dose across seven plaque sizes had a standard deviation ͑k =1͒ less than 2% for the model 6711 source and less than 3% for the model 200 source. The largest differences are at the outer sclera, and differences in these ratios are less than or equal to 1% for both sources at depths of 1-10 mm from the inner sclera. These results are supported by Thomson et al. 20 In contrast, MC heterogeneity corrections for off-axis locations are generally more sensitive to plaque size than on-axis corrections due to variations in penumbra with plaque diameter. While the dose to the outer sclera relative to the prescription dose is significantly higher for 10-14 mm plaques, dose to the outer sclera as reported in these 16 mm comparisons is typical of the 16 mm and larger plaques. 19 Therefore, the results for 16 mm plaque presented here will not be identical to those for other plaque diameters, especially at off-axis locations.
These findings suggest that the lens dose for plaque positions #1-#4 can be significantly different from those calculated using current widely used dosimetry methods. This will affect scientific evaluations such as dose response and radiation-induced retinopathy and cataract. 4, 32 When comparisons of normal tissue toxicity and administered doses are made with other treatment modalities such as external-beam photon or proton radiotherapy, accuracy of dose calculations becomes even more crucial.
In this study, we focused on a particular, widely used seed model for each of the radionuclides. This was motivated by the results from a recent study by Thomson and Rogers who reported on the variation of dose distributions for eye plaque therapy as a function of seed model. 30 They identified six seed models to have sufficient air-kerma strength for eye plaque therapy. 30 In their study, dose decreases relative to homogeneous TG-43 assumptions varied only slightly with seed model, demonstrating variations up to 2%. Points of interest doses are lower for 103 Pd seed models than with 125 I with the possible exception of the sclera. Based on the results of the study by Thomson and Rogers, results presented herein for the specific models of 125 I and 103 Pd sources are typical of other similar source models. Regardless, the decrease in dose to the four points of interest for organs at risk from 103 Pd in comparison to 125 I was expected due to the lower penetration of 103 Pd photons with lower average photon energy than 125 I. This study focused on the dosimetry of a COMS plaque for which extensive high quality clinical outcome data are available in the literature. 4, 9, 16, 32 Following the COMS trials, many clinical studies using variations of eye plaques have reported equivalent or better clinical outcomes. It may be useful to reanalyze their dosimetry using modern MC methods. Dosimetry for plaques of other models will generally differ considerably from dosimetry for COMS-style plaques. 33 Heterogeneity corrections depend critically on plaque design and can be significant in magnitude. For example, Thomson et al. 33 recently reported calculated dose distributions for treating iris melanoma using several plaque designs which are drastically different from those for COMS; they found that although dose distributions computed under the TG-43 approach are identical, doses computed with MC methods ͑with plaques fully modeled͒ differ substantially.
It should be noted that the issues regarding the impact on the prescription dose following the adoption of MC-based calculations also apply to the adoption of PS with the heterogeneity corrections turned on. PS users are perhaps at risk of overdosing patients up to 20% if heterogeneity corrections are used and the prescribed dose is not modified appropriately. This issue is a major topic of interest for the upcoming report of an AAPM Task Group ͑TG-129͒.
Many clinics currently prefer to use plaques that are thinner than the original COMS design and other models are manufactured without lipped edges. Also, many users no longer use a Silastic insert. Therefore, since the quantitative dosimetry conclusions reported in this work are specific to the standard COMS plaque design, they may not apply to different designs-particularly if used in a non-COMS fashion. Regardless of plaque design, we expect that the lower energy 103 Pd-derived photons are less likely to reach most normal ocular structures compared to 125 I. The approximate 10% and 20% dose reductions at the prescription point for 125 I and 103 Pd, respectively, warrant attention by the medical community using eye plaque brachytherapy and should be considered in the context of clinical standards and local control rates at each institution when the clinics adopt MC dose calculation methods for clinical dosimetry. 
V. CONCLUSIONS
Five different dose calculation systems were compared for ophthalmic plaque brachytherapy dose calculations, and included Pinnacle v8.0dp1, BrachyVision v8.1 PS v5.3.9, and two MC codes ͑MCNP5 v1.40 and BrachyDose/EGSnrc͒. Comparisons of dose values at various points along the plaque's central-axis and at off-axis points of interest ͑optic disk center, lacrimal gland center, fovea, and lens center͒ were made for a COMS 16 mm eye plaque loaded with 13 125 I ͑model 6711͒ or 103 Pd ͑model 200͒ seeds. The plaque was placed at eight different positions on a model eye. Dose differences between TG-43 based conventional TPS and MC codes exceeding 10% are observed and increased up to 92% for dose points located further away at off-axis locations where shielding is not accounted for. These results help justify consideration of TPS using advanced dose calculation algorithms based on MC methods to more accurately predict dose delivered to patients with intraocular melanoma undergoing plaque brachytherapy.
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